Checkpoint inhibitors (pembrolizumab · nivolumab · ipilimumab)
Immune checkpoint inhibitor
Acute interstitial nephritis with long latency.
AIN
ModerateOpen →
PD-1 immune checkpoint inhibitor
Toripalimab
Loqtorzi · PD-1 inhibitor
First FDA-approved drug for nasopharyngeal carcinoma; renal risk is class-typical immune-mediated interstitial nephritis.
ModeratePD-1 checkpoint inhibitor era; first FDA approval (Oct 2023) for nasopharyngeal carcinoma. · approved 2023
Recurrent or metastatic nasopharyngeal carcinoma (first-line, with gemcitabine and cisplatin)Recurrent, unresectable, or metastatic nasopharyngeal carcinoma (monotherapy, after platinum-based chemotherapy)
Signature kidney injury
Acute Interstitial Nephritis
Representative incidence3%
Drug-specific renal data are limited; reasoning from the PD-1 class is required. Across PD-1/PD-L1 agents, clinically significant immune-related AKI (predominantly AIN) occurs in roughly 1-5% of patients, with attributable PD-L1-related AKI under 1% in one large cohort but pooled estimates as high as ~3-5% with platinum co-therapy. In the JUPITER-02 registrational trial, immune-related adverse events were more frequent with toripalimab (54.1% vs 21.7%) and grade ≥3 irAEs occurred in 9.6%, but kidney-specific irAEs were not individually quantified.
Source: Class estimate from PD-L1/ICI cohorts (Seethapathy 2020, PMID 33102962; Wanchoo 2017 review, PMID 28076863; ASON position statement, PMID 39455026); trial-level irAE data from JUPITER-02 (PMID 38015220). Toripalimab-specific renal incidence not separately reported.
Toxicity fingerprint
Tap a signature to trace where it strikes the nephron.
0%incidence
SeverityModerate
ReversibilityPartially reversible
Evidence0 refs
Nephron map
Glomerulus
Distal Tubule / Collecting Duct
InterstitiumSupporting tissue around the tubules
Acute Interstitial Nephritis
Immune-mediated inflammation of the renal interstitium — the signature kidney injury of checkpoint inhibitors.
Mechanism of kidney injury
Class-mechanistic: PD-1 blockade abrogates peripheral immune tolerance, permitting activated T-cell infiltration of the renal interstitium and a delayed-type hypersensitivity-like acute (tubulo)interstitial nephritis. Loss of PD-1 signaling may also unmask reactivity to tubular or drug-hapten antigens, which is why concurrent AIN-associated drugs (PPIs, NSAIDs, antibiotics) and platinum co-therapy amplify risk. Less commonly, checkpoint activation drives immune-complex or podocyte-pattern glomerular disease and electrolyte handling disturbances.
Clinical presentation
Typically a subacute, often asymptomatic rise in serum creatinine weeks to months into therapy. Sterile pyuria, low-grade subnephrotic proteinuria, and occasionally eosinophilia or other concurrent irAEs (rash, colitis, thyroiditis, hepatitis) may be present. Frank nephrotic syndrome or active urinary sediment should prompt consideration of a superimposed glomerular lesion. Definitive diagnosis is by kidney biopsy showing interstitial inflammation.
Anticancer mechanism
Humanized IgG4 monoclonal antibody that binds the PD-1 receptor on T cells and blocks engagement by its ligands PD-L1/PD-L2, releasing the inhibitory checkpoint and restoring antitumor T-cell activity. In recurrent/metastatic nasopharyngeal carcinoma it is combined with gemcitabine-cisplatin chemotherapy.
Management
Hold toripalimab for significant AKI and exclude prerenal, obstructive, and platinum-related ATN causes. Per American Society of Onco-nephrology guidance, suspected ICI-AIN is treated by withholding the checkpoint inhibitor, discontinuing concurrent AIN-culprit drugs, and initiating corticosteroids (e.g., prednisone ~0.5-1 mg/kg/day with taper) for grade ≥2 injury; kidney biopsy is favored when feasible to confirm AIN and guide steroid duration. Many patients recover at least partial renal function. Rechallenge can be considered after recovery for lower-grade events with close monitoring, but carries recurrence risk and should be individualized.
Risk factors
- Concurrent platinum (cisplatin) chemotherapy — used in the nasopharyngeal carcinoma regimen
- Concomitant AIN-associated drugs (proton pump inhibitors, NSAIDs, antibiotics)
- Prior or concurrent extrarenal immune-related adverse events
- Pre-existing chronic kidney disease or reduced baseline GFR
- Volume depletion / nephrotoxin exposure from cisplatin
Prevention
- Baseline and periodic serum creatinine and urinalysis monitoring before each cycle
- Review and deprescribe unnecessary PPIs/NSAIDs that can prime AIN
- Maintain euvolemia and apply standard cisplatin nephroprotection (hydration, magnesium repletion)
- Early nephrology referral and low threshold for biopsy on unexplained creatinine rise
Note · Renal-specific evidence for toripalimab is thin; this profile reasons primarily from the PD-1/PD-L1 checkpoint-inhibitor class and registrational JUPITER-02 safety data, which is stated explicitly. Incidence figure is a class-derived estimate, not a toripalimab-measured value.
Clinical depth
Renal dose adjustment
No starting dose adjustment for renal impairment is specified; toripalimab is a monoclonal antibody cleared by reticuloendothelial proteolysis, not renal excretion. Pharmacologic dose modification for kidney function is not required; instead, management is by holding/discontinuing for immune-related toxicity per severity grade. Mild-to-moderate renal impairment is not expected to alter exposure.
Dialyzability & ESKD dosing
Not dialyzable. As a ~150 kDa IgG4 monoclonal antibody it is not removed by hemodialysis or peritoneal dialysis; no supplemental dosing is needed in dialysis patients.
Differential diagnosis
Distinguish immune-related AIN from cisplatin-induced acute tubular necrosis (concurrent in the NPC regimen), prerenal azotemia from chemotherapy-related GI losses, contrast or other nephrotoxin exposure, and obstructive uropathy from pelvic/nasopharyngeal disease. A superimposed checkpoint-related glomerular lesion (e.g., podocytopathy, immune-complex GN) should be considered when nephrotic-range proteinuria or hematuria is present. Kidney biopsy is the reference standard separating AIN from ATN.
Monitoring
- Serum creatinine/eGFR before each infusion and periodically thereafter
- Urinalysis with protein and microscopy (sterile pyuria, proteinuria)
- Serum electrolytes including magnesium and potassium (cisplatin co-therapy)
- Surveillance for concurrent extrarenal irAEs
- Spot urine protein-to-creatinine ratio if proteinuria emerges
Key trials & series
- JUPITER-02 (NCT03581786): phase 3 toripalimab + gemcitabine-cisplatin vs placebo in recurrent/metastatic NPC — improved PFS and OS; basis for FDA approval
- POLARIS-02: phase 2 toripalimab monotherapy in previously treated recurrent/metastatic NPC supporting the monotherapy indication
Clinical pearls
- First-ever FDA-approved therapy for nasopharyngeal carcinoma (Oct 2023); a PD-1 inhibitor, so default kidney signature is immune-related AIN.
- Toripalimab-specific renal toxicity is not separately quantified in trials — incidence is inferred from the PD-1/PD-L1 class and is likely low (~1-5%).
- Concurrent cisplatin in the NPC regimen is itself nephrotoxic (ATN) and a recognized amplifier of ICI-AIN; separating the two often requires biopsy.
- Onset is characteristically late (months), so an unexplained creatinine creep well into therapy should raise suspicion.
- Being a monoclonal antibody, it needs no renal dose adjustment and is not dialyzable; the lever is immunosuppression and drug hold, not dose reduction.
Beyond the kidney
Class-level context for the major non-renal toxicities of pd-1 immune checkpoint inhibitors.
Endocrine
Thyroiditis, hypophysitis, diabetes
- Thyroiditis, hypophysitis, type-1 diabetes
Gastrointestinal
Diarrhea, colitis, mucositis, perforation
- Immune colitis
Hepatic / Liver
Transaminitis, hepatitis, VOD/SOS
- Immune hepatitis
Pulmonary
Pneumonitis, ILD, effusions, hypertension
- Pneumonitis
Dermatologic
Rash, HFS, SJS/TEN, vitiligo
- Rash, vitiligo, rarely SJS/TEN
Evidence
6 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkToripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial.Mai HQ et al. · JAMA 2023 · PMID 38015220Pivotal phase 3 registrational trial (final analysis) supporting FDA approval; source of trial-level immune-related adverse event rates (irAEs 54.1% vs 21.7%; grade >=3 irAEs 9.6%).PMIDToripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial.Mai HQ et al. · Nature Medicine 2021 · PMID 34341578Primary JUPITER-02 phase 3 report establishing efficacy and the overall safety profile of toripalimab plus gemcitabine-cisplatin.PMIDDiagnosis and management of immune checkpoint inhibitor-associated nephrotoxicity: a position statement from the American Society of Onco-nephrology.Herrmann SM et al. · Kidney International 2024 · PMID 39455026Authoritative onco-nephrology consensus on incidence, AIN pathophysiology, corticosteroid management, biopsy role, and rechallenge for ICI-AKI — basis for the management and monitoring guidance.PMIDIncidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 Inhibitors.Seethapathy H et al. · Kidney International Reports 2020 · PMID 33102962Large cohort quantifying ICI-related AKI; attributable PD-L1-related AKI <1%, median onset ~99 days, and the role of concurrent AIN-culprit drugs — anchors the incidence and onset estimates.PMIDAdverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review.Wanchoo R et al. · American Journal of Nephrology 2017 · PMID 28076863Class review establishing AIN as the dominant PD-1 renal lesion, late onset relative to CTLA-4 agents, steroid responsiveness, and reported incidence ranges (up to ~10-29%).PMIDImmune checkpoint inhibitors induce acute interstitial nephritis in mice with increased urinary MCP1 and PD-1 glomerular expression.Martinez Valenzuela L et al. · Journal of Translational Medicine 2024 · PMID 38702780Mechanistic model showing cisplatin + anti-PD-L1 synergistically induce AIN (40% incidence) with urinary MCP-1 as a biomarker — supports the platinum co-therapy amplification mechanism relevant to the NPC regimen.